F
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Fariba Jousheghany's research focuses on cancer immunology and vaccine development, particularly in the context of breast cancer treatment. Her work investigates the immune responses elicited by novel cancer vaccines, such as the P10s-PADRE vaccine, when combined with neoadjuvant chemotherapy in patients with ER-positive breast cancer. Studies have examined both humoral and cellular immune responses, including the induction of cancer-specific T-cell responses and the identification of peripheral immune correlates of tumor response.
Her recent publications also explore the role of tumor-associated glycans and exosomes in macrophage interactions, suggesting potential targets for therapeutic intervention. Further research involves characterizing antibodies to specific tumor-associated antigens, like chondroitin sulfate proteoglycan 4 (CSPG4), and their reactivity. Jousheghany's work is supported by collaborations with researchers at the University of Arkansas for Medical Sciences, including Behjatolah Monzavi‐Karbassi, Bernice Nounamo, Steven R. Post, and Eric R. Siegel. She has an h-index of 14 with 41 total publications and 691 total citations.
Metrics
- h-index: 14
- Publications: 43
- Citations: 694
Selected Publications
-
Abstract 2908: SR-A antagonism remodels the myeloid population of tumor immune microenvironment, expands CD8-positive T cells, and enhances antitumor efficacy in vivo (2026)
-
Class A scavenger receptors promote tumor progression and induce a unique macrophage phenotype in a mouse model of spontaneous breast cancer (2026)
-
Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment (2024)
-
Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine (2024)
-
Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A (2024)
-
Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine (2023)
-
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen (2023)
-
Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients (2022)
-
P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses (2021)
Collaboration Network
Top Collaborators
Behjatolah Monzavi‐Karbassi
University of Arkansas for Medical Sciences
7 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A
Showing 5 of 7 shared publications
Eric R. Siegel
University of Arkansas for Medical Sciences
6 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
Showing 5 of 6 shared publications
Thomas Kieber‐Emmons
University of Arkansas for Medical Sciences (US)
6 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
Showing 5 of 6 shared publications
Issam Makhoul
4 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
Bernice Nounamo
University of Arkansas for Medical Sciences
4 shared publications
In database
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
- Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment
Saddam Mohammed Ibrahim
University of Arkansas for Medical Sciences (US)
2 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Muhammad Abu‐Rmaileh
University of Arkansas for Medical Sciences (US)
2 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Lora J. Rogers
University of Arkansas for Medical Sciences
2 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Sergio Piña‐Oviedo
University of Arkansas for Medical Sciences (US)
2 shared publications
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Ginell R. Post
University of Arkansas for Medical Sciences
2 shared publications
In database
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients
Steven R. Post
University of Arkansas for Medical Sciences
2 shared publications
In database
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A
Thomas J. Kelly
University of Arkansas for Medical Sciences
2 shared publications
In database
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
- Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A
Emily Blitz
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A
- Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment
Vinay Raj
University of Arkansas at Pine Bluff (US)
2 shared publications
- Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine
John J. Lee
University of Arkansas for Medical Sciences (US)
1 shared publication
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses
Similar Researchers
Based on overlapping research topics
John P. Lee
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Breast Cancer Treatment Studies
Immune Response and Inflammation
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Breast Cancer Treatment Studies
Immune Response and Inflammation
Teresa Evans
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Vaccine Coverage and Hesitancy
Immune Response and Inflammation
Behjatolah Monzavi‐Karbassi
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Vaccine Coverage and Hesitancy
Immune Response and Inflammation
Nagalo Bolni
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Vaccine Coverage and Hesitancy
Stacy A Petty
University of Arkansas for Medical Sciences
Breast Cancer Treatment Studies
Immune Response and Inflammation